<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641977</url>
  </required_header>
  <id_info>
    <org_study_id>19802015</org_study_id>
    <nct_id>NCT02641977</nct_id>
  </id_info>
  <brief_title>Longterm Followup of Patients With Rheumatoid Arthritis Treated With Methotrexate</brief_title>
  <acronym>MTX</acronym>
  <official_title>Longterm Followup of Patients With Rheumatoid Arthritis Treated With Methotrexate Enroled in the Ratingener Rheuma-Kohorte</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longterm followup of patients with rheumatoid arthritis 30 years after starting a baseline
      treatment with Methotrexate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective. 30-year follow-up of rheumatoid arthritis (RA) patients treated with methotrexate
      (MTX) in the 1980s to analyze the association of the degree of response to MTX with long-term
      mortality.

      Methods. In this observational cohort study, 271 RA patients who had started treatment with
      MTX between 1980 and 1987 were included (mean age 58 years, mean disease duration 8.5 years).
      One year after baseline, the treatment response to MTX was evaluated. Responders were defined
      as patients with at least 20% improvement. Thereafter, assessments were performed at 10 and
      18 years after baseline. This re-evaluation was done to provide the data after 30 years of
      follow-up. Standardized mortality ratios (SMR) are calculated, Cox regression and logistic
      regression are performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>30 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">271</enrollment>
  <condition>External Causes of Morbidity and Mortality</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with rheumatoid arthritis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  rheumatoid arthritis

          -  treatment with methotrexate

          -  active disease

        Exclusion Criteria:

          -  low disease activity

          -  previous treatment with methotrexate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietmar MJ Krause, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Bochum, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Internistische und rheumatologische Praxis Gladbeck</name>
      <address>
        <city>Gladbeck</city>
        <zip>45964</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 6, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruhr University of Bochum</investigator_affiliation>
    <investigator_full_name>Dietmar Krause, MD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

